CD98 is a glycoprotein [1][2] that is a heterodimer composed of SLC3A2 and SLC7A5 that forms the large neutral amino acid transporter (LAT1). LAT1 is a heterodimeric membrane transport …

Due to the significant up-regulation of LAT1 expression in several human tumors, LAT1 has been an attractive transporter for targeted delivery of amino acid-derived anticancer drugs and …

Mar 13, 2019 · Here we report the cryo-electron microscopy structures of human LAT1–4F2hc alone and in complex with the inhibitor 2-amino-2-norbornanecarboxylic acid at resolutions of …

Dec 25, 2024 · Enables L-amino acid transmembrane transporter activity and secondary active transmembrane transporter activity. Involved in carboxylic acid transport; thyroid hormone …

Feb 14, 2025 · LAT1 (SLC7A5) transports large neutral amino acids and plays pivotal roles in cancer proliferation, immune response and drug delivery. Despite recent advances in …

L-Type Amino Acid Transporter 1 (LAT1) mediates the uptake of essential amino acids and its expression is upregulated during the progression of several cancers. We will review the …

In this article, we review the available data on the role of LAT1 in the regulation of GBM biology, including its potential role in the tumour microenvironment, particularly in infiltrating-peripheral …

Mar 23, 2021 · LAT1 (SLC7A5) is one of the representative light chain proteins of heteromeric amino acid transporters, forming a heterodimer with its heavy chain partner 4F2hc (SLC3A2). …

LAT1 is a heterodimeric, sodium- and pH-independent amino acid transporter. ‘L-type’ in its traditional name refers to its classification with ‘System L’, i.e. the leucine-preferring group of …

LAT1 (also known as SLC7A5), is defined as a heteromeric amino acid transporter (HAT) interacting with the glycoprotein CD98 (SLC3A2) through a conserved disulfide to uptake not …

The inhibition of LAT1 suppresses protein synthesis by downregulating the mTORC1 signaling pathway and mobilizing the general amino acid control (GAAC) pathway in cancer cells.

The large neutral amino acid transporter 1 (LAT1, or SLC7A5) is a sodium- and pH-independent transporter, which supplies essential amino acids (e.g., leucine, phenylalanine) to cells.

Feb 1, 2022 · LAT1 is essential for cancer cell growth because the pharmacologic inhibition and knockdown/knockout of LAT1 suppress the proliferation of cancer cells and the growth of …

Due to the significant up-regulation of LAT1 expression in several human tumors, LAT1 has been an attractive transporter for targeted delivery of amino acid-derived anticancer drugs and …

Nov 14, 2019 · The human L-type amino acid transporter 1 (LAT1), also known as SLC7A5, catalyzes the transport of large neutral amino acids across the plasma membrane.

May 16, 2019 · In this review, we summarize the most recent advances in our understanding of the role of LAT1 in cancer and highlight preclinical studies and drug developments underlying …

LAT1 (SLC7A5) is a transporter for both the uptake of large neutral amino acids and a number of pharmaceutical drugs. It is expressed in numerous cell types including T-cells, cancer cells …

Apr 24, 2018 · LAT1 (SLC7A5) is a sodium and pH-independent transmembrane transporter that forms a heterodimeric complex with the glycoprotein 4F2hc (CD98, SLC3A2) to import large …

Oct 23, 2023 · The L-type amino acid transporter 1 (LAT1) affects the activity of mTORC1 through upstream regulators that sense intracellular amino acid levels. While mTORC1 activation by …